Pfizer Investor Presentation — January 2019

Document content

Earnings Teleconference

January 29, 2019 Introduction

Senior Vice President,

Fourth Quarter 2018 Earnings Fourth Quarter 2018 Earnings

3 Forward -Looking Statements and

Non-GAAP Financial Information

 Our discussions during this conference call will include forward- looking statements about, among other things, our anticipated future

operating and financial performance, business plans and prospects, in- line products and product candidates, including anticipated

regulatory submissions, data read- outs, study starts, approvals, performance, timing of exclusivity and potential benefits of Pf izer's

products and product candidates, strategic reviews, capital allocation, business- development plans, the benefits expected from t he

reorganization of our commercial operations into three businesses effective at the beginning of our 2019 fiscal year, our acquisitions

and other business development activities, our proposed transaction with GSK to combine our respective consumer healthcare businesses into a new consumer healthcare joint venture, our ability to successfully capitalize on growth opportunities and prospects, manufacturing and product supply and plans relating to share repurchases and dividends that are subject to substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements.

Additional information regarding these factors can be found in Pfizer’s Annual Report on Form 10- K for the fiscal year ended

December 31, 2017 and in our subsequent reports on Form 10- Q, including in the sections thereof captioned “Risk Factors” and

“Forward -Looking Information and Factors That May Affect Future Results”, as well as in our subsequent reports on Form 8- K, all of

which are filed with the U.S. Securities and Exchange Commission and available at www.sec.gov and www.pfizer.com